This company seems to have been delisted
Reason: Acquired by LG Chem
Last recorded trade on: March 24, 2023
Source: http://investor.aveooncology.com/news-releases/news-release-details/lg-chem-completes-acquisition-aveo-oncology
Reason: Acquired by LG Chem
Last recorded trade on: March 24, 2023
Source: http://investor.aveooncology.com/news-releases/news-release-details/lg-chem-completes-acquisition-aveo-oncology
AVEO Oncology
AVEO
C$20.65
Share price
0.00%
Change (1 day)
169.18%
Change (1 year)
Categories
P/S ratio for AVEO Oncology (AVEO)
P/S ratio on March 24, 2023 (TTM) : 5.53
According to AVEO Oncology 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 18.1. At the end of 2022 the company had a P/S ratio of 3.02.
P/S ratio history for AVEO Oncology from 2010 to 2022
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2022 | 3.02 | -20.76% |
| 2021 | 3.81 | -86.2% |
| 2020 | 27.6 | 692.08% |
| 2019 | 3.49 | -90.68% |
| 2018 | 37.4 | -14.1% |
| 2017 | 43.6 | 167.41% |
| 2016 | 16.3 | 322.7% |
| 2015 | 3.85 | 58.97% |
| 2014 | 2.42 | -96.69% |
| 2013 | 73.3 | 301.26% |
| 2012 | 18.3 | 305.41% |
| 2011 | 4.51 | -61.31% |
| 2010 | 11.6 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Biogen BIIB | 1.91 | -65.47% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 4.28 | -22.62% | 🇺🇸 USA |
 Merrimack Pharmaceuticals MACK | N/A | N/A | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.00 | -63.79% | 🇺🇸 USA |
 Eli Lilly LLY | 14.0 | 152.82% | 🇺🇸 USA |
 Amgen AMGN | 4.78 | -13.48% | 🇺🇸 USA |